Williams Cancer Institute

Menu
Menu
Ovarian cancer · Interventional immuno-oncology

Platinum-resistant doesn’t mean out of options. We unmask what the tumor hides.

For ovarian cancer that has stopped responding to chemotherapy — we treat the tumor directly and re-engage your immune system.

Personalized

Minimally invasive

Immune-activating

Outpatient

In plain terms

What we do, in three paragraphs.

Advanced ovarian cancer that has become platinum-resistant or progressed after PARP-inhibitor maintenance has limited options — and standard immunotherapy alone hasn’t changed outcomes, because ovarian tumors are largely immune-“cold”. Our approach treats the tumor directly: ablation plus intratumoral immunotherapy, often using PEF to treat pelvic and abdominal disease without injuring nearby bowel.
There’s a specific opportunity in BRCA-mutated and HRD-positive cancers: these carry more neoantigens the immune system can in principle recognize — but the tumor still hides them. Breaking the tumor open exposes those signals and turns it “hot” — AblationVax, aiming for the abscopal effect, including across abdominal spread.
It’s designed for platinum-resistant or refractory disease, progression after PARP inhibitors or mirvetuximab, BRCA-mutated disease seeking neoantigen-driven activation, or a few growing spots on systemic therapy. We coordinate with your gynecologic-oncology team; most patients finish in about a week. Results vary.

One needle, one session: ablation plus immunotherapy delivered where the cancer lives.

AblationVax: the treated tumor teaches your immune system to attack cancer body-wide.

Real outcomes

Platinum-resistant and post-PARP disease.

Ovarian cancer is largely immune-cold; checkpoint monotherapy has not changed standard care. Our approach: convert cold tumors to immune-responsive at the tumor site.

Individual results vary. These outcomes represent specific patient cases and are not guaranteed for all patients.

Where our approach fits

Treatment options by stage.

Find your diagnosis below to see what standard care offers, where we add to it, and what role our approach plays.

Frontline

Standard care
Surgery + platinum-taxane ± bevacizumab → PARP maintenance (BRCA/HRD+).
What we add
Our approach is rarely first-line.
Standard care first

Recurrent platinum-sensitive

Standard care
Platinum-doublet → PARP.
What we add
Selected cases for additional immune activation.
Adjunct to standard care

Our primary focus

Recurrent platinum-resistant

Standard care
Single-agent sequences (PLD, weekly paclitaxel, topotecan, mirvetuximab).
What we add
Ablation + intratumoral immune re-engagement.

The peritoneal microenvironment is immunosuppressive — we amplify immunity at accessible disease to turn cold hot.

Systemic immune activation

Post-PARP

Standard care
After PARP and FRα ADC, available lines narrow.
What we add
Multi-agent intratumoral cocktails as next-line consideration.
Re-engagement

Beyond ablation alone

Destroy the tumor, then teach your immune system to finish the job.

Standard approaches
Our approach — AblationVax
Surgery + platinum → PARP → resistant single agents → FRα ADC.
Ablation + intratumoral immunotherapy for platinum-resistant or post-PARP progression.

IV checkpoint blockade: largely ineffective in ovarian cancer.
Delivered directly into the tumor rather than through the bloodstream. The aim is to concentrate treatment at the tumor site and limit whole-body exposure.

No established immune option after PARP and ADC failure.
Multi-agent intratumoral cocktails as next-line consideration.

Why this approach for ovarian cancer?

Treats tumors near critical structures

Peritoneum, bowel, bladder, ureters — non-thermal PEF treats pelvic and abdominal disease where thermal ablation risks bowel injury.

Converts “cold” tumors into “hot” targets

Ovarian’s immune-cold biology is well-documented. Ablation + intratumoral immunotherapy addresses the root cause.

Aims for systemic response

Researchers are studying whether treating one tumor can help produce a response in untreated tumors elsewhere in the abdomen or body—an abscopal response.

Ovarian-specific breakthrough

BRCA-driven antigenicity + cold-tumor conversion.

“BRCA-mutated ovarian cancer should be more immunogenic — but the local microenvironment suppresses recognition. We expose those neoantigens through ablation and amplify recognition through intratumoral delivery.”

— Dr. Jason R. Williams

Neoantigen exposure in BRCA / HRD+

Higher mutation loads generate more potential neoantigens. Ablation exposes them; intratumoral immunotherapy amplifies the response.

Costimulatory + checkpoint combos

OX40 / CD40 agonists delivered intratumorally provide the costimulation checkpoint monotherapy lacks in cold tumors.

The combination

CpG, OX40 / CD40, and checkpoint inhibitors intratumorally for patients who have exhausted PARP, bevacizumab, and FRα-targeted options.

“Ovarian cancer is mostly immune-cold, but BRCA / HRD-positive disease has neoantigens hidden behind microenvironmental suppression. We unmask them.” — Dr. Williams

Beyond the procedure: whole-patient support.

We optimize your entire system for the best possible response — and coordinate with the team you already have.

Gut microbiome optimization

Diet, probiotics, and related therapies to support a stronger immunotherapy response.

Off-label protocols

Strategic use of repurposed medications to enhance immune response.

Personalized cocktails

Multi-agent immunotherapy tailored to your specific cancer.

Oncologist coordination

We work alongside your current chemo and radiation team.

What to expect

Your path to treatment.

1

Case review

We review your CT abdomen / pelvis, PET, and biomarker reports (BRCA, HRD score, MSI, FRα).

2

Protocol design

A personalized cocktail tuned to BRCA / HRD status, immune profile, and prior lines.

3

Procedure week

Image-guided PEF or cryoablation + intratumoral immunotherapy. Outpatient.

4

Follow-up

CA-125 and imaging at 6–8 weeks, coordination with your home team.

Procedure ~1 hour

Recovery ~2 hours

All outpatient

Is this right for you?

You may be a candidate if:

✓Platinum-resistant or platinum-refractory disease
✓Progression on PARP inhibitors (BRCA / HRD+)
✓Progression on mirvetuximab (FRα+)
✓Oligoprogressive disease on systemic therapy
✓BRCA-mutated disease seeking neoantigen-driven amplification

It may not be suitable if:

—Bowel obstruction without a management plan
—Massive ascites limiting procedural feasibility
—Active severe infection
—Uncorrectable bleeding disorders
—Very poor performance status (ECOG ≥ 3)

Each case is individually evaluated by Dr. Williams’ team.

Track record

Innovation for ovarian cancer.

2014

Multi-agent intratumoral protocols

The AblationVax concept.

2015

Combination protocols reported

Yervoy / Opdivo / CpG / PV-10 combinations.

Now

PEF + multi-agent intratumoral protocols

For platinum-resistant and post-PARP ovarian cancer.

Ready to move forward?

There is more ahead. Take the next step with confidence.

Complimentary evaluation.

Dr. Williams’ team will personally review your case and imaging — no cost, no obligation.

Or email info@williamscancerinstitute.com

Beverly Hills · San Jose del Cabo · Mexico City — most patients complete treatment in one week

(theme footer continues — owned by Astra)

Menu

Email Signup